Literature DB >> 26261675

Clear cell variant of diffuse large B-cell lymphoma: a case report and review of the literature.

Yongjie Xue1, Qiulan Wang2, Xuejiao He1.   

Abstract

Diffuse large B cell lymphoma (DLBCL) is a diffuse proliferation of large neoplastic B lymphoid cells with nuclear size equal to or exceeding that of normal macrophage nuclei. The DLBCL morphological variants are centroblastic, immunoblastic, T-cell- and histiocyte-rich, anaplastic, plasmablastic, anaplastic lymphoma kinase-positive, and primary mediastinal large B-cell lymphoma (PMBCL). These histopathologically-recognized morphological variants respond differently to treatment and have distinct prognoses. We report a case of a 43-year-old patient who presented pain in the lower abdomen that had begun four months prior. Ultrasound-guided biopsy revealed epithelial cell features and a partial alveolar growth pattern. We discovered large diffuse areas comprising large cells with slightly irregular nuclei and very clear cytoplasm. These features were similar to those of clear cell carcinoma in renal tissue, suggesting the possibility of an epithelial neoplasm. To test this possibility, immunohistochemistry for cluster designation markers was performed, but the diffuse areas were found to be positive only for CD45. Additional immunohistochemistry was performed, and the diffuse areas were found to be positive for CD20, CD79a, P53, and Mum-1. Based on these characteristics, a diagnosis of a clear cell variant of DLBCL was made, and the patient was treated with chemotherapy. Precise histological diagnosis is crucial for clinical management and ultimately for patient survival. There has been one additional report of a case of clear cell DLBCL, in outside the mediastinum. The features we identified can be used to define a new subtype of DLBCL. The expression of P53 and Mum-1 suggest a poor prognosis.

Entities:  

Keywords:  CD20; CD45; Diffuse large B-cell lymphoma; clear cell; morphology; newly defined entities; retroperitoneal

Mesh:

Substances:

Year:  2015        PMID: 26261675      PMCID: PMC4526009     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  21 in total

1.  Diffuse large B-cell lymphoma and its variants.

Authors:  Mara Dominis; Sonja Dzebro; Slavko Gasparov; Anita Pesut; Rajko Kusec
Journal:  Croat Med J       Date:  2002-10       Impact factor: 1.351

2.  A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma.

Authors:  George Wright; Bruce Tan; Andreas Rosenwald; Elaine H Hurt; Adrian Wiestner; Louis M Staudt
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-04       Impact factor: 11.205

Review 3.  Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach.

Authors:  Jeremy S Abramson; Margaret A Shipp
Journal:  Blood       Date:  2005-04-26       Impact factor: 22.113

4.  Large cleaved and immunoblastic lymphoma may represent two distinct clinicopathologic entities within the group of diffuse large B-cell lymphomas.

Authors:  Pascale De Paepe; Ruth Achten; Gregor Verhoef; Iwona Wlodarska; Michel Stul; Vera Vanhentenrijk; Marleen Praet; Chris De Wolf-Peeters
Journal:  J Clin Oncol       Date:  2005-08-29       Impact factor: 44.544

5.  Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL).

Authors:  Nicolas Mounier; Josette Briere; Christian Gisselbrecht; Jean-Francois Emile; Pierre Lederlin; Catherine Sebban; Francoise Berger; Andre Bosly; Pierre Morel; Herve Tilly; Reda Bouabdallah; Felix Reyes; Philippe Gaulard; Bertrand Coiffier
Journal:  Blood       Date:  2003-02-06       Impact factor: 22.113

6.  Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.

Authors:  Christine P Hans; Dennis D Weisenburger; Timothy C Greiner; Randy D Gascoyne; Jan Delabie; German Ott; H Konrad Müller-Hermelink; Elias Campo; Rita M Braziel; Elaine S Jaffe; Zenggang Pan; Pedro Farinha; Lynette M Smith; Brunangelo Falini; Alison H Banham; Andreas Rosenwald; Louis M Staudt; Joseph M Connors; James O Armitage; Wing C Chan
Journal:  Blood       Date:  2003-09-22       Impact factor: 22.113

7.  A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy.

Authors:  William W L Choi; Dennis D Weisenburger; Timothy C Greiner; Miguel A Piris; Alison H Banham; Jan Delabie; Rita M Braziel; Huimin Geng; Javeed Iqbal; Georg Lenz; Julie M Vose; Christine P Hans; Kai Fu; Lynette M Smith; Min Li; Zhongfeng Liu; Randy D Gascoyne; Andreas Rosenwald; German Ott; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; David L Jaye; Louis M Staudt; Wing C Chan
Journal:  Clin Cancer Res       Date:  2009-08-25       Impact factor: 12.531

Review 8.  Diffuse large B-cell lymphoma.

Authors:  Maurizio Martelli; Andrés J M Ferreri; Claudio Agostinelli; Alice Di Rocco; Michael Pfreundschuh; Stefano A Pileri
Journal:  Crit Rev Oncol Hematol       Date:  2013-01-30       Impact factor: 6.312

9.  Diffuse large B-cell lymphoma of non-germinal center B-cell type of the heart in an immunocompetent woman: an autopsy case.

Authors:  Tadashi Terada
Journal:  Med Oncol       Date:  2010-01-12       Impact factor: 3.064

Review 10.  Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapy.

Authors:  Antonino Carbone; Annunziata Gloghini; Yok-Lam Kwong; Anas Younes
Journal:  Ann Hematol       Date:  2014-05-29       Impact factor: 3.673

View more
  2 in total

1.  Primary gastric anaplastic lymphoma kinase-negative anaplastic large-cell lymphoma.

Authors:  Chen Tian; Yizhuo Zhang
Journal:  Onco Targets Ther       Date:  2016-09-13       Impact factor: 4.147

2.  Clear cell change in follicular adenoma of the thyroid. A diagnostic challenge.

Authors:  José Fernando Val-Bernal; María Martino
Journal:  Rom J Morphol Embryol       Date:  2020       Impact factor: 1.033

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.